-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate

Benzinga·04/07/2025 21:27:06
Listen to the news
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 27.03 percent increase over losses of $(0.74) per share from the same period last year.